- Company
- Forxiga will maintain its price for 10 months in KOR
- by Jung, Sae-Im Jun 2, 2023 05:38am
- The prices of AstraZeneca’s SGLT-2 inhibitor ‘Forxiga (dapagliflozin)’ and combination drug ‘Xigduo’ will stay as is until February next year. On the 1st, the Seoul Administrative Court’s 1st Administrative Division accepted the suspension of execution filed by AstraZeneca against the Ministry of Health and Welfare to cancel the drug p
- Company
- BMS and Gilead compete tightly in HBV drug market in KOR
- by Nho, Byung Chul Jun 2, 2023 05:38am
- BMS’s Baraclude and Gilead Science’s Viread are fiercely competing in the KRW 200 billion original hepatitis B treatment market. Based on drug distribution results, sales of Baraclude and Viread, the No.1 and No.2 products in the HBV market in 2022, were tallied at KRW 69.5 billion and KRW 62.8 billion, respectively. Just last yea
- Company
- K-Pharma Bio ASCO launch table
- by Hwang, Jin-joon Jun 1, 2023 05:43am
- Pipeline clinical results of major domestic pharmaceutical bio companies such as Yuhan Corp. were disclosed at ASCO. According to the industry on the 31st, the abstract of a paper scheduled to be presented at ASCO, which will be held in Chicago, USA from June 2nd to 6th (local time), was recently released. ASCO is a major international academ
- Company
- The share of the domestic bio-industry is around 1%
- by Hwang, Jin-joon Jun 1, 2023 05:42am
- "It has been confirmed that the domestic bio-industry accounts for around 1% of the global market. In order for Korea's bio-industry, which is a latecomer, to secure global competitiveness, policy, and institutional support is needed." Lee Jeong-Seok, chairman of the Korea Biopharmaceutical Association, said this at the ‘Biohealth Industry Nati
- Company
- ↓Sales of Nexavar and Lenvima &↑Sales of Cabometyx
- by Kim, Jin-Gu Jun 1, 2023 05:39am
- The second-line treatment Stivaga also decreased by 23%, and Only 2nd and 3rd line treatment Cabometyx grew by 11%. Sales of major liver cancer treatments plummeted. Nexavar (Sorafenib) sales decreased by nearly half in the first year, and Lenvima (Lenvatinib) sales also decreased by 41%. It is analyzed that the impact of the immuno-oncology
- Company
- The only non-reimbursed Evrysdi struggle in the market
- by Jung, Sae-Im Jun 1, 2023 05:39am
- It has been 1 year and 6 months since the only oral spinal muscular atrophy (SMA) treatment, ‘Evrysdi (risdiplam),’ has been released in the Korean market. However, the company is having trouble posting sales in Korea. This is in stark contrast to how the same product exceeded the sales of 'Zolgensma' and is comparable to the sales of 'S
- Company
- SK bioscience's coronavirus vaccine, approved in the UK
- by Kim, Jin-Gu Jun 1, 2023 05:39am
- While SKYCovione, a domestic COVID-19 vaccine, obtained approval in the UK, SK bioscience predicted that global expansion would begin in earnest after the WHO EUL listing expected next year. According to the pharmaceutical industry on the 31st, SK bioscience received official approval for SKYCovione from the British MHRA on the 26th (local t
- Company
- Keytruda is expected to enter the domestic market
- by Eo, Yun-Ho Jun 1, 2023 05:38am
- Keytruda, an immuno-oncology drug, is aiming to expand indications for early lung cancer in Korea. According to the related industry, MSD Korea is a non-small adult stage 1B (tumor size of 4 cm or more), stage 2 or 3A after surgical excision of the PD-1 inhibitor Keytruda (pembrolizumab) and use of a platinum complex chemotherapy agent. A po
- Company
- Lyumjev can be prescribed at general hospitals
- by Eo, Yun-Ho May 31, 2023 05:37am
- According to related industries, Korea Lily's Lyumjev has passed the Drug Committee of medical institutions such as Samsung Seoul Hospital, Seoul National University Hospital, Seoul Asan Hospital, Gangnam Severance Hospital, and Seoul National University Bundang Hospital. This drug was approved in Korea in December 2021, and insurance ben
- Company
- Samsung Bioepis, Soliris biosimilar approved in Europe
- by Chon, Seung-Hyun May 31, 2023 05:36am
- Samsung Bioepis announced on the 30th that it has obtained item permission from EC for Episcli, a biosimilar of Soliris, a treatment for rare diseases. On March 30, after obtaining a positive opinion for sales approval from CHMP under the EMA, the final approval was obtained two months later. Episcli is the first biopharmaceutical in hematolo
